52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
HOOKIPA Collaborates With Merck To Evaluate HB-200 With Keytruda In Advanced Head And Neck Cancers
Merck Sees Potential U.S. Authorization For COVID-19 Drug Molnupiravir Before Year-End
Merck And Ridgeback Biotherapeutics Announce Initiation Of Pivotal Phase 3 Move-Ahead Study Evaluating Molnupiravir For Post-Exposure Prophylaxis Of Covid-19 Infection
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.
Biotechnology & Drugs
2000 Galloping Hill Rd
Kenneth C. Frazier
Executive Chairman of the Board
Robert M. Davis
President, Chief Executive Officer, Director
Chief Financial Officer, Executive Vice President
Franklin K. Clyburn
President, Human Health, Head of Human Health Commercial and Marketing
Dean Y. Li
President - Merck Research Laboratories
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* MERCK CEO SAYS BUSINESS DEVELOPMENT IS A HIGH PRIORITY; WILL CONTINUE TO BE APPROPRIATELY AGGRESSIVE IN EVALUATING POTENTIAL TARGETS - MORGAN STANLEY CONF
Drugmaker Merck & Co Inc said on Monday it sees potential U.S. emergency use authorization for its experimental COVID-19 antiviral treatment, molnupiravir, before year-end.
Pfizer Inc and Merck & Co Inc announced on Wednesday new trials of their experimental oral antiviral drugs for COVID-19 as the race to develop an easy-to-administer treatment for the potentially fatal illness heats up.
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection.
Merck & Co Inc and partner Ridgeback Biotherapeutics said on Wednesday they had begun enrolling patients in a late-stage trial of their experimental drug molnupiravir for prevention of COVID-19 infection. (Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra...
U.S. drugmaker Merck & Co Inc has initiated a rolling submission to Health Canada for Molnupiravir, an oral antiviral therapy treatment for COVID-19, it said in a statement on Friday.
* AUSTRALIA'S TGA: PROVISIONAL DETERMINATION MEANS TGA HAS MADE DECISION THAT MSD ELIGIBLE TO APPLY FOR PROVISIONAL REGISTRATION FOR MOLNUPIRAVIR IN ARTG
Some of Germany's best-known brands and industry bellwethers lifted their full-year sales and profit expectations on Thursday, citing a broad demand recovery from the effects of the pandemic.
Merck & Co reported quarterly revenue on Thursday that topped Wall Street estimates, as sales of its Gardasil vaccine bounced back and demand for blockbuster cancer drug Keytruda remained strong.
* MERCK & CO CEO SAYS CO HAS FINANCIAL FLEXIBILITY TO CONSIDER DEALS OF ALL SIZES
Merck & Co Inc on Thursday reported a 49% fall in second-quarter profit after it spun off its women's health and biosimilar assets into Organon in June. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
Merck & Co Inc said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy.
India's Hetero Labs said on Friday it sought emergency use nod from the local regulator for Merck's COVID-19 drug molnupiravir, after interim data from a late-stage trial showed it helped reduce hospitalisations and speed up recovery in mild cases.
Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial in India for Merck & Co's experimental anti-viral drug to treat mild COVID-19 in non-hospitalised patients.
Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.
Merck & Co Inc said on Wednesday the U.S. government has agreed to pay about $1.2 billion for 1.7 million courses of its experimental COVID-19 treatment, if it is proven to work in an ongoing large trial and authorized by U.S. regulators.
Merck & Co Inc said on Wednesday the U.S. government has agreed to buy about 1.7 million courses of the company's experimental COVID-19 drug, molnupiravir, for about $1.2 billion, if it is authorized in the country. (Reporting by Manojna Maddipatla in Bengaluru; Editing...
AstraZeneca Plc's drug Lynparza reduced the risk of relapse and death in breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday.
Germany's Merck on Wednesday said its Life Science business, a leading maker of biotech lab supplies and gear, saw core earnings jump more than 43% in the first quarter, driven by the pharma industry's efforts to fight the coronavirus pandemic.
German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.